Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity
Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity出 版 物：《世界最新医学信息文摘》 (World Latest Medicine Information)
年 卷 期：2015年第5期
页 面：9-9页
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题：Rapamycin m TOR Glucose intolerance Insulin Diabetes
摘 要：Rapamycin, a specific inhibitor for m TOR complex 1, is an FDA-approved immunosuppressant for organ transplant. Recent developments have raised the prospect of using rapamycin to treat cancer or diabetes and to delay aging. It is therefore important to assess how rapamycin treatment affects glucose homeostasis. Here, we show that the same rapamycin treatment reported to extend mouse life span significantly impaired glucose homeostasis of aged mice. Moreover, rapamycin treatment of lean C57B/L6 mice reduced glucose-stimulated insulin secretion in vivo and ex vivo as well as the insulin content and beta cell mass of pancreatic islets. Confounding the diminished capacity for insulin release, rapamycin decreased insulin *** multitude of rapamycin effects thus all lead to glucose intolerance. As our findings reveal that chronic rapamycin treatment could be diabetogenic, monitoring glucose homeostasis is crucial when using rapamycin as a therapeutic as well as experimental reagent.
同方期刊数据库